Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of semi-depot house dust mite allergen extract during initial SCIT in children and adolescents with allergic rhinitis and/or allergic asthma
ChiCTR-OIH-17012492Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2016
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of House dust mite allergen extract in allergic rhinitis (AR) and allergic asthma, sponsored by Beijing Children's Hospital. Primary endpoints: Skin prick test, Serum specific IgE and 2 more. Started Apr 2016; status: recruiting.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic asthma
Beyond the preview
Go deeper on ChiCTR-OIH-17012492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIH-17012492.